Endocr Relat Cancer. 2017 Feb 17. pii: ERC-16-0463. doi: 10.1530/ERC-16-0463. [Epub ahead of print]
Murray A1, Madden S2, Synnott NC3, Klinger R4, O'Connor D5, O'Donovan N6, Gallagher W7, Crown J8, Duffy M9.
- There have been strong hints that high vitamin D dosing along with adjusting cofactors may allow treating of many Cancers.
- Note1: Breast Cancer is 4.6 times more likely to occur if have poor Vitamin D Receptor (see below)
- Note2: Reducing Calcium intake and drinking lots of water both reduce "calcemic potential,"
Items in both VitaminDWiki categories Breast Cancer and Vitamin D Receptor are listed here:
- Poor Vitamin D Receptor does not increase the risk of Breast Cancer (but the opposite is true) – umbrella meta-analysis Sept 2024
- An activated Vitamin D Receptor fights Autoimmune Diseases, Infections, Cancers, etc. – Dec 2023
- Breast Cancer risk reduced if consume butyrate - Dec 2023
- Breast cancer spreads to bone if poor vitamin D Receptor (no surprise) – Oct 2022
- Some breast cancers may be treated RNA changes caused by Vitamin D – March 2022
- Breast Cancer, Vitamin D, and genes – Welsh Nov 2021
- After lactation Vitamin D levels are low, increased risk of Breast Cancer, vitamin D should decrease risk – Aug 2021
- Breasts process Vitamin D and change gene activation, might prevent breast cancer if given more Vit. D – July 2021
- Breast cancer associated with Vitamin D Receptor (14th study) – Oct 2019
- After breast cancer treatment 4,000 IU of Vitamin D was not enough to help if have poor Vitamin D receptor – June 2019
- Breast Cancer death 1.8 X more likely if poor Vitamin D Receptor – April 2019
- Breast Cancer and Vitamin D review – March 2018
- Women with Breast Cancer were 16.9 times more likely to have a poor Vitamin D Receptor – Jan 2019
- Cancer treatment by Vitamin D sometimes is restricted by genes – Oct 2018
- Two chemicals increase the Vitamin D receptor and decrease the growth of breast cancer cells in the lab - March 2018
- Breast Cancer reduces receptor and thus blocks Vitamin D to the cells – several studies
- Vitamin D receptor as a target for breast cancer therapy (abstract only) – Feb 2017
- Breast Cancer was 4.6 times more likely if have a poor Vitamin D Receptor – Dec 2016
- Increased Breast Cancer metastasis if low vitamin D or poor VDR – Feb 2016
- Increased risk of some female cancers if low vitamin D (due to genes) – meta-analysis June 2015
- Vitamin D receptor in breasts and breast cancer vary with race – March 2013
- Breast Cancer incidence change by 40 percent with vitamin D receptor genes – Oct 2012
- Genes breast cancer and vitamin D receptor - Sept 2010
Vitamin D Receptor category has the following
Vitamin D tests cannot detect Vitamin D Receptor (VDR) problems
A poor VDR restricts Vitamin D from getting in the cells
It appears that 30% of the population have a poor VDR (40% of the Obese )
Several diseases protect themselves by deactivating the Vitamin D receptor. Example: Breast Cancer
- - - - - - - -
The Vitamin D Receptor is associated with many health problems
Some health problems, such as Breast Cancer, Diabetes, and COVID protect themselves by reducing VDR activation
55 health problems associated with poor VDR
A poor VDR is associated with the risk of 55 health problems click here for details
The risk of 48 diseases at least double with poor VDR as of Jan 2023 click here for details
Some health problem, such as Breast Cancer reduce the VDR
VDR at-home test $29 - results not easily understood in 2016
There are hints that you may have inherited a poor VDR
How to increase VDR activation
Compensate for poor VDR by increasing one or more:
Increasing | Increases |
1) Vitamin D supplement Sun Ultraviolet -B | Vitamin D in the blood and thus in the cells |
2) Magnesium | Vitamin D in the blood AND in the cells |
3) Omega-3 | Vitamin D in the cells |
4) Resveratrol | Vitamin D Receptor |
5) Intense exercise | Vitamin D Receptor |
6) Get prescription for VDR activator paricalcitol, maxacalcitol? | Vitamin D Receptor |
7) Quercetin (flavonoid) | Vitamin D Receptor |
8) Zinc is in the VDR | Vitamin D Receptor |
9) Boron | Vitamin D Receptor ?, etc |
10) Essential oils e.g. ginger, curcumin | Vitamin D Receptor |
11) Progesterone | Vitamin D Receptor |
12) Infrequent high concentration Vitamin D Increases the concentration gradient | Vitamin D Receptor |
13) Sulfroaphane and perhaps sulfur | Vitamin D Receptor |
14) Butyrate especially gut | Vitamin D Receptor |
15) Berberine | Vitamin D Receptor |
Note: If you are not feeling enough benefit from Vitamin D, you might try increasing VDR activation. You might feel the benefit within days of adding one or more of the above
Far healthier and stronger at age 72 due to supplements Includes 6 supplements that help the VDR
Increased risk of diseases if poor VDR
Increased risk associated with a poor Vitamin D Receptor
Note: Some diseases reduce VDR activation
those with a * are known to decrease activation
Considerable epidemiological evidence suggests that high levels of circulating vitamin D (VD) are associated with a decreased incidence and increased survival from cancer, i.e., VD may possess anti-cancer properties. The aim of this investigation was therefore to investigate the anti-cancer potential of a low calcemic vitamin D analogue, i.e., inecalcitol and compare it with the active form of vitamin D, i.e., calcitriol, in a panel of breast cancer cell lines (n = 15). Using the MTT assay, IC50 concentrations for response to calcitriol varied from 0.12 µM to >20 µM, while those for inecalcitol were significantly lower, ranging from 2.5 nM to 63 nM (p = 0.001). Sensitivity to calcitriol and inecalcitol was higher in VD receptor (VDR)-positive compared to VDR-negative cell lines (p = 0.0007 and 0.0080, respectively) and in ER-positive compared to ER-negative cell lines (p = 0.043 and 0.005, respectively). Using RNA-seq analysis, substantial but not complete overlap was found between genes differentially regulated by calcitriol and inecalcitol. In particular, significantly enriched gene ontology terms such as cell surface signalling and cell communication were found following treatment with inecalcitol but not with calcitriol. In contrast, ossification and bone morphogenesis were found significantly enriched following treatment with calcitriol but not with inecalcitol. Our preclinical results suggest that calcitriol and inecalcitol can inhibit breast cancer cell line growth, especially in cells expressing ER and VDR. As inecalcitol, is significantly more potent than calcitriol and has low calcemic potential, it should be further investigated for the treatment of breast cancer.
PMID: 28213567 DOI: 10.1530/ERC-16-0463
Publisher wants $30 for the PDF
4072 visitors, last modified 01 Mar, 2017, |